Therapeutic potential of RUNX1 and RUNX2 in bone metastasis of breast cancer
- 3 June 2023
- journal article
- editorial
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 27 (6) , 413-417
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Triple-negative breast cancer: challenges and opportunities of a heterogeneous diseaseNature Reviews Clinical Oncology, 2016
- RUNX1 prevents oestrogen-mediated AXIN1 suppression and β-catenin activation in ER-positive breast cancerNature Communications, 2016
- Tumour exosome integrins determine organotropic metastasisNature, 2015
- Role of RUNX2 in Breast CarcinogenesisInternational Journal of Molecular Sciences, 2015
- Clinical utilities of aromatase inhibitors in breast cancerInternational Journal of Women's Health, 2015
- Expression of RUNX1 Correlates with Poor Patient Prognosis in Triple Negative Breast CancerPLOS ONE, 2014
- Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancerEuropean Journal of Cancer, 2012
- RUNX1 and its understudied role in breast cancerCell Cycle, 2011
- Runx2 Regulates G Protein-coupled Signaling Pathways to Control Growth of Osteoblast ProgenitorsJournal of Biological Chemistry, 2008
- Estrogen Resistance Caused by a Mutation in the Estrogen-Receptor Gene in a ManNew England Journal of Medicine, 1994